These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10999925)

  • 1. Screening for Down's syndrome. Data do not support study's claim.
    Norgaard-Pedersen B
    BMJ; 2000 Sep; 321(7263):763; author reply 764-5. PubMed ID: 10999925
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for Down's syndrome. Serum screening programmes are effective and safe.
    Wald NJ; Hackshaw AK; Huttly W
    BMJ; 2000 Sep; 321(7263):763-4; author reply 764-5. PubMed ID: 10999927
    [No Abstract]   [Full Text] [Related]  

  • 3. Screening for Down's syndrome. Biochemical screening offers advantages.
    Boyd PA; Jefferies M; Chamberlain PF; Crocker AJ
    BMJ; 2000 Sep; 321(7263):762; author reply 764-5. PubMed ID: 10999923
    [No Abstract]   [Full Text] [Related]  

  • 4. Screening for Down's syndrome. Serum screening shows a clear benefit across age groups.
    McCune GS; Stock AS; Foakes A
    BMJ; 2000 Sep; 321(7263):762-3; author reply 764-5. PubMed ID: 10999924
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prenatal diagnosis of Down's syndrome: prediction from maternal serum markers].
    Zilberstein T; Maymon E
    Harefuah; 1998 Mar; 134(5):393-6. PubMed ID: 10909560
    [No Abstract]   [Full Text] [Related]  

  • 6. Antenatal screening policies for Down's syndrome. Serum screening for Down's syndrome is better than age screening.
    Christiansen M; Larsen SO; Nørgaard-Pedersen B
    BMJ; 2002 Nov; 325(7371):1034; author reply 1034. PubMed ID: 12420332
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prenatal screening for Down's syndrome].
    Qin Q; Christiansen M; Norgaard-Pedersen B
    Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):694-7. PubMed ID: 9639772
    [No Abstract]   [Full Text] [Related]  

  • 8. The prospects for "preventing" Down's syndrome in an English region.
    Forster DP
    Rev Epidemiol Sante Publique; 1980 Dec; 28(4):423-30. PubMed ID: 6452660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prenatal investigations for Down's syndrome: medical-technical considerations and dilemmas arising from current screening methods].
    Grijseels EW; Laudy JA; Galjaard RJ; Wildschut HI
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2166-71. PubMed ID: 15559409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Screening by maternal serum markers for Down's syndrome].
    Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the risk of Down's syndrome in antenatal screening and the gestation at which this risk applies.
    Morris JK; Wald NJ
    J Med Screen; 2007; 14(1):5-7. PubMed ID: 17362564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Secondary prevention of Down's syndrome in Czechoslovakia 1975-1980].
    Kucera J
    Cesk Pediatr; 1982 Jul; 37(7):404-8. PubMed ID: 6215132
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, Regional Hospital.
    Lamlertkittikul S; Chandeying V
    J Med Assoc Thai; 2007 Oct; 90(10):1970-6. PubMed ID: 18041410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
    Spencer K
    Ann Clin Biochem; 2005 Jan; 42(Pt 1):30-40. PubMed ID: 15802030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current methods of prenatal screening for Down syndrome and other fetal abnormalities.
    Saller DN; Canick JA
    Clin Obstet Gynecol; 2008 Mar; 51(1):24-36. PubMed ID: 18303497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antenatal screening policies for Down's syndrome. Audit of Down's syndrome screening is not valid.
    Wald NJ; Huttly W; Hackshaw AK
    BMJ; 2002 Nov; 325(7371):1034; author reply 1034. PubMed ID: 12411371
    [No Abstract]   [Full Text] [Related]  

  • 17. Socioeconomic and state-level differences in prenatal diagnosis and live birth prevalence of Down's syndrome in the United States.
    Khoshnood B; Pryde P; Blondel B; Lee KS
    Rev Epidemiol Sante Publique; 2003 Dec; 51(6):617-27. PubMed ID: 14967994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Median parameters for Down's syndrome screening should be calculated using a moving time-window method.
    Reynolds TM; Aldis J
    Ann Clin Biochem; 2008 Nov; 45(Pt 6):567-70. PubMed ID: 18768535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Down's syndrome. Statistical modelling is best tool for formulating screening policy.
    Cuckle H
    BMJ; 2000 Sep; 321(7263):763; author reply 764-5. PubMed ID: 10999926
    [No Abstract]   [Full Text] [Related]  

  • 20. [Maternal serum screening for Down's syndrome].
    Muller F
    Ann Biol Clin (Paris); 2002; 60(6):689-92. PubMed ID: 12446233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.